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Abstract
Background:  Phosphatidylinositol-3,4,5-triphosphate (PtdInsP3) signaling is elevated in many
tumors due to loss of the tumor suppressor PTEN, and leads to constitutive activation of Akt, a
kinase involved in cell survival. Reintroduction of PTEN in cells suppresses transformation and
tumorigenicity. While this approach works in-vitro, it may prove difficult to achieve in-vivo. In this
study, we investigated whether inhibition of growth factor signaling would have the same effect as
re-expression of PTEN.
Methods: Dominant negative IGF-I receptors were expressed in CHO and U87 cells by retroviral
infection. Cell proliferation, transformation and tumor formation in athymic nude mice were
assessed.
Results: Inhibition of IGF-IR signaling in a CHO cell model system by expression of a kinase-
defective IGF-IR impairs proliferation, transformation and tumor growth. Reduction in tumor
growth is associated with an increase in apoptosis in-vivo. The dominant-negative IGF-IRs also
prevented growth of U87 PTEN-negative glioblastoma cells when injected into nude mice. Injection
of an IGF-IR blocking antibody α IR3 into mice harboring parental U87 tumors inhibits tumor
growth and increases apoptosis.
Conclusion: Inhibition of an upstream growth factor signal prevents tumor growth of the U87
PTEN-deficient glioma to the same extent as re-introduction of PTEN. This result suggests that
growth factor receptor inhibition may be an effective alternative therapy for PTEN-deficient
tumors.
Background
Phosphatidylinositol-(3,4,5)-trisphosphate (PIP3) is one
of the major intracellular second messengers regulating
growth, metabolism and vesicular trafficking [for reviews
see refs [1–3]]. The level of (PIP3) in the cell is determined
by the balance of kinase and phosphatase activity. PI-
3Kinase activity is acutely regulated and a number of iso-
forms have been cloned that are activated in response to
various stimuli [4]. The major phosphatidylinositol-3-
phosphate phosphatase in cells is the tumor suppressor
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PTEN [5,6]. This protein has a tonic inhibitory effect on
PI-3Kinase signaling by reversing the 3'-phosphorylation.
PTEN is altered or deleted in many human cancers [7–10].
In-vitro, cells that are deficient in PTEN show elevated PI-
3Kinase signaling [11]. Reintroduction of PTEN in a vari-
ety of cancer cells, including glioma, breast, bladder and
ovarian cancer cells, causes G1 arrest, inhibits tumorigen-
esis, and promotes anoikis [12–14]. Mechanistically, Akt
activity is decreased, cell motility is decreased, expression
of two cyclin-dependent kinase inhibitors p27 and p21 is
increased, cyclin D1 is down-regulated, Rb phosphoryla-
tion is inhibited, and signaling via Grb2/SOS is sup-
pressed [11,15]. The link between PTEN and cell growth is
underscored by genetic experiments in mice. PTEN knock-
out mice die in-utero due to extensive overgrowth of the
cephalic and caudal regions [12,16]. PTEN +/- hetero-
zygous mice have a predisposition to tumors in multiple
tissues often with loss of the second allele [17,18]. In-vit-
ro, PTEN-/- embryonic stem cells and fibroblasts display
increased proliferation and decreased sensitivity to apop-
tosis.
The PI-3Kinase-dependent activation of Akt is thought to
play a central role in the cell survival pathway in many
cells [7,19,20]. Elevated Akt activity and protein is found
in many PTEN-deficient cancer cells. Akt directly phos-
phorylates and inactivates the pro-apoptotic proteins
ASK1, BAD, caspase 9 [21–24]. Akt also induces the ex-
pression of the anti-apoptotic Bcl-2 and c-FLIP proteins,
and suppresses the cell cycle inhibitor p27KIP[25–28].
This later effect is via the phosphorylation and inactiva-
tion of the forkhead family of transcription factors AFX,
FKHR and FKHR-L1. Although it is often assumed that el-
evated Akt activity is responsible for the increased survival
of cancer cells, Akt activity is not the only pathway that is
essential for cell survival. The MAPK pathway can also
protect cells from apoptosis, as can constitutive activation
of Stat3 signaling [29,30].
The IGF-I Receptor is a member of the large family of ty-
rosine kinase growth factor receptors. Signaling by the
IGF-IR has been studied in many different cell types and is
important for proliferation, survival, motility, adhesion,
transformation, tumor formation and metastasis [for re-
views see refs [31,32]]. The receptor can directly phospho-
rylate the insulin receptor substrate 1 (IRS-1) and Shc
proteins in the intact cell causing activation of PI-3Kinase
and ras signaling [33]. More recently, it has been shown
that the IGF-IR signals via the Gβγ  subunits of the heterot-
rimeric Gi complex to stimulate PI-3Kinase and ras, and
also activates the JAK/Stat pathway to cause phosphoryla-
tion of Stat3 [34,35].
What is the evidence for the involvement of IGF-IR signal-
ing in proliferation and cancer? Elegant studies in knock-
out mice have delineated the contribution of IGF-I, IGF-II
and the IGF-I receptor to fetal growth [for review see ref
[36]]. Embryonic fibroblasts derived from IGF-IR knock-
out embryos (R-cells) do not grow in serum-free medium,
despite supplementation with a wide variety of other
growth factors, and grow more slowly in media contain-
ing serum than wild-type cells [for reviews see refs
[37,38]]. Additionally, all phases of the cell cycle are pro-
longed in the null cells suggesting that the IGF-IR is re-
quired throughout the cell cycle. A functional IGF-I
receptor is required for successful cell transformation.
IGF-IR-/- cells are not transformed by overexpression of
SV40 T antigen, activated ras, or EGF or PDGF receptors.
Transformation appears to involve autocrine stimulation
as IGF-I production and secretion is increased in normal
cells following transformation by SV40 T antigen, but the
null cells cannot respond to the IGF-I so do not transform.
Interfering with the IGF signaling system can inhibit the
growth of cancer cells in-vitro and in-vivo. Treatment with
antagonistic peptide analogs of IGF-I, antisense oligos, or
an adenovirus expressing IGF-IR antisense cRNA, prevents
proliferation of cells in monolayers, transformation, and
growth in athymic nude mice. This includes multiple hu-
man tumor cell lines including glioblastoma, melanoma,
ovarian carcinoma, prostatic carcinoma, and breast carci-
nomas). [for reviews see refs [31],[39–41]]. The IGF-IR ap-
pears to function in transformation both by preventing
apoptosis through activation of Akt and by stimulating
proliferation through the ras-MAPK cascade. IGF-I can
prevent c-myc-induced apoptosis in rat-l fibroblasts, and
neuronal apoptosis due to serum-starvation. IGF-IR-/-
cells can proliferate in monolayers in the presence of se-
rum but undergo apoptosis when put in suspension and
are more sensitive to chemotherapeutic reagents. There is
also evidence implicating the IGF-IR in metastasis. IGF-I
produces a chemotactic response in human melanoma
cells and antisense to the IGF-IR mRNA prevents metasta-
sis in the murine carcinoma cell H-59.
In this study, we wanted to determine if disruption of IGF-
I signaling could prevent growth of a tumor cell lacking
PTEN. Elevated PI-3Kinase can be normalized by reintro-
duction of PTEN to reduce PIP3 levels, but it has not been
shown that this effect can also be achieved by disruption
of an upstream signal that stimulates PI-3Kinase activity.
We have previously demonstrated the overexpression and
hormone-independent activation of the IGF-IR in primary
breast cancers [42]. Similar overexpression of the IGF-IR
and the ligands IGF-I and IGF-II have been seen in human
gliomas and astrocytomas [43–46]. Because of the impor-
tant role for the IGF-IR in cell survival, we investigated
whether a dominant negative IGF-IR could inhibit growth
of the U87 glioma. This glioma is deficient in PTEN andBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/15
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shows constitutive activation of Akt, which can be inacti-
vated by re-introduction of PTEN [47].
Materials and Methods
Materials and Cell Culture
Antiphosphotyrosine antibodies (pY20) were from BD-
Transduction Labs (Lexington, KY). Matrigel was from
Becton-Dickinson (Bedford, MA) Athymic nude mice
were purchased from Charles River (Wilmington, MA).
Enhanced chemiluminescence reagents were from Amer-
sham (Piscataway, NJ). [3H]-thymidine (20 Ci/mmol)
was from Perkin-Elmer/NEN Life Sciences (Boston, MA).
Unless noted, all other reagents were supplied by Sigma
Chemical Co. (St. Louis, MO) or Fisher Scientific Co.
(Springfield, NJ). CHO cells were maintained in Hams
F12 with 25 mM glucose with 50 units/ml penicillin, 50
µg/ml streptomycin, and 10% FCS in a 10 % CO2 envi-
ronment. U87 glioma cells were maintained in MEM-Ear-
le's medium with non-essential amino acids, 1 mM
sodium pyruvate, 10% FCS, 2 mM Glutamax and gen-
tamycin sulphate in a 10% CO2 environment.
Immunoblotting
Cells were serum starved for 16 h in 12-well plates, then
stimulated with IGF-I (10 or 100 ng/ml) for 5 min at
37°C. The cells were washed with ice-cold phosphate-
buffered saline and solubilized in 2 ×  SDS-sample buffer
containing 2 mM sodium orthovanadate and 200 mM so-
dium fluoride. The proteins were denatured by boiling for
5 min, then were separated by electrophoresis on 7.5%
SDS-PAGE, and transferred to PVDF membranes. The fil-
ter was blocked with 3% BSA in TBS with 0.1% Tween 20
(T-TBS) for 30 min and incubated with the anti-phospho-
tyrosine antibodies at a dilution of 1:1000. The filters
were washed with T-TBS for 30 min and incubated with
horseradish-peroxidase conjugated secondary antibodies,
and tyrosine-phosphorylated proteins were visualized by
enhanced chemiluminescence.
Measurement of thymidine incorporation
Cells were grown to 75% confluence in six-well cluster
plates. The growth medium was replaced with serum-free
Ham's F12 for 36 h. Cells were stimulated with IGF-I at
the indicated concentrations for 18 h. Cells were pulsed
with [3H]-thymidine, 2 µCi/ml, for 1 h at 37°C. The cells
were washed five times in PBS, solubilized, the DNA pre-
cipitated with 10% trichloroacetic acid at 4°C, and count-
ed in an scintillation counter.
Production of pseudo-typed retrovirus
The wild-type IGF-IR cDNA or a mutant cDNA, which
contained a methionine substitution for lysine 1003 in
the ATP-binding site of the kinase domain, were cloned
into the retroviral vector pLPONL [57]. The pseudo-typed
viruses were generated and purified by the UCSD Viral
Vector Core. The plasmids were co-transfected into 293
cells with an expression vector for the Vesicular Stomatitis
Virus-G protein. This coat protein allows the virus to be
concentrated and confers greater tropism. Cell culture su-
pernatants and cells were harvested and the virus concen-
trated. Viruses were titered on NIH3T3 cells and the
number of G418 resistant colonies counted. A control vi-
rus containing the E. coli β -galactosidase gene was ob-
tained from the Viral Vector Core.
Growth in Soft Agar
Cells were trypsinized and 104 cells plated in 35 mm petri
dishes in complete medium containing 0.35% agarose
over a layer of 0.7% agarose in complete medium. Cells
were allowed to grow for 14–21 days or until colonies
were >125 µm in diameter. Fresh medium was layered
above the agarose every 3–5 days. Colonies were stained
with Crystal Violet and counted.
Tumor Growth in Athymic Nude Mice
Housing and all procedures using nude mice were ap-
proved by the animal care committee at UCSD. The cells
for injection were trypsinized in sterile PBS, pelleted by
centrifugation at 300 ×  g for 2 min. and washed twice in
sterile saline. Cells were resuspended in 100 µl sterile sa-
line and counted using a hemacytometer. The appropriate
number of cells was diluted into 50 µl sterile saline and
then added to an equal volume of sterile Matrigel on ice.
This suspension was injected subcutaneously on the rear
flank of athymic nude mice using a sterile syringe and 22-
gauge needle. Mice were observed on a twice-weekly basis
to check for tumor growth. Tumors were measured with
calipers in three dimensions and tumor volume calculated
assuming the tumors were ellipsoid. At the end of the
study, the tumors were excised, measured, weighed, and
then fixed in 10% formalin. Tumors were embedded in
paraffin, sectioned and stained with hematoxylin-eosin or
for apoptosis using the TUNEL assay (Roche, Indianapo-
lis, IN).
Results and Discussion
Inhibition of the IGF-I receptor by expression of a kinase 
inactive mutant inhibits proliferation of Chinese hamster 
ovary (CHO) cells
Before embarking on studies in human tumor cells, we
verified that our dominant negative approach would work
in a model system. To inhibit the IGF-IR, we took advan-
tage of the fact that the IGF-I receptor is a hetero-tetramer.
Activation of the native receptor requires the trans-phos-
phorylation of two kinase domains [48]. Hence, expres-
sion of an excess of kinase-defective IGF-I receptors causes
the formation of hybrid molecules containing one half an
endogenous wild-type receptor and the other half a ki-
nase-defective transfected receptor. These hybrids should
be kinase inactive and signaling incompetent. Similar ap-BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/15
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proaches have been used successfully in other studies [49–
52].
Initially, we tested Chinese hamster ovary (CHO) cells
that had been stably transfected with expression vectors
for kinase-inactive or wild type IGF-I receptors [53]. The
parental CHO cell line expresses ~50,000 endogenous
IGF-IRs, the transfected wild-type (CHO-WT) cell line ex-
presses ~250,000 IGF-IRs, and the kinase-defective (CHO-
MK) cell line expresses ~250,000 mutant IGF-IRs. Thus,
the transfected cells express the human IGF-IR at approxi-
mately five fold higher levels than the endogenous recep-
tor. The mutant receptor contains a lysine to methionine
(MK) point mutation at position 1003 in the ATP binding
site of the kinase domain and has no measurable kinase
activity. Two clonal lines expressing the MK receptor were
used with identical results.
We assessed the ability of the IGF-IRs of each cell line to
undergo autophosphorylation in response to increasing
concentrations of IGF-I. Cells were stimulated with in-
creasing concentrations of IGF-I, and whole cell lysates
immunoblotted for tyrosine-phosphorylated proteins. As
expected, autophosphorylation of the IGF-IRs was ob-
served in the CHO and CHO-WT cells but very little was
seen in two different clones of CHO-MK cells, indicating
that the kinase-defective receptors inhibited the endog-
enous wild-type hamster receptors (Figure 1A). The inhi-
Figure 1
Expression of a kinase inactive IGF-IR impairs tumorigenesis. CHO cells express 5 ×  104 IGF-IRs, CHO-WT cells express 2 ×
105 wild-type IGF-IRs, and the CHO-MK cells express 2 ×  105 mutant IGF-IRs that contain a Lysine to Methionine point muta-
tion in the ATP-binding site (MK1003). Panel A: IGF-I stimulated whole cell tyrosine phosphorylation. Serum-starved cells were
stimulated with IGF-I (10 or 100 ng/ml) for 5 min and whole cell extracts immunoblotted for phosphotyrosine. The positions of
the β -subunit of the IGF-IR and IRS-1 are indicated. Panel B: Serum-starved CHO or CHO-MK cells were stimulated with
increasing concentrations of IGF-I for 18 h then pulsed with 3H-thymidine for 1 h. DNA was precipitated with TCA and
counted. Panel C: ten thousand cells were plated in soft agar in complete medium for 14–21 days. Colonies > 125 µm in diam-
eter were counted after staining with crystal violet. Panel D: ten million cells were injected subcutaneously into the rear flank
of athymic nude mice. Tumor size was measured with calipers every few days. Graph shows mean tumor volume (± SEM) as a
function of time. Panel E: Mice were euthanized after 21 days and the tumors excised, weighed and fixed for staining. Graph
shows mean tumor weight (± SEM).
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bition was not complete however, as phosphorylation of
IRS1, the major endogenous substrate in these cells, is still
preserved at the higher dose of IGFI but inhibited at the
lower dose. This is likely due to the level of receptor ex-
pression. The transfected receptors are expressed at four
fold the level of the endogenous receptors. Assuming sto-
chastic assembly of tetramers, 4% of receptors should be
homodimers of signaling competent receptors that can
phosphorylate IRS1. To confirm that the kinase-defective
receptors were functioning in a dominant-negative fash-
ion, we studied the ability of CHO and CHO-MK cells to
incorporate 3H-thymidine into DNA in response to IGF-I
stimulation. Serum-starved cells were stimulated with in-
creasing concentrations if IGF-I and then pulsed with 3H-
thymidine. The ability of the CHO-MK cells to incorpo-
rate thymidine in response to IGF-I is markedly dimin-
ished as compared to the parental cell line (Figure 1B).
We then tested colony formation in soft agar as an indica-
tor of cellular transformation. Cells were trypsinized,
counted and equivalent numbers of cells plated in soft
agar in complete medium. Cells were cultured for 14 – 21
days and then the number of colonies counted. Overex-
pression of the wild-type IGF-IRs increased the number of
colonies, and overexpressing the kinase-defective recep-
tors reduced the number of colonies by 60% (Figure 1C).
Not only did we observe a difference of the number of col-
onies, but CHO-MK colonies were smaller than either the
parental CHO or CHO-WT colonies (data not shown).
We next studied the ability of each of these cell lines to
form tumors in athymic nude mice. Ten million (107)
cells from each cell line were injected subcutaneously into
the flanks of five athymic nude mice. Tumor size was
measured biweekly. The mice were euthanized at the end
of three weeks and the tumors excised and weighed (Fig-
ure 1D & 1E). At this high level of innoculum, there was
no difference in tumor incidence (data not shown). How-
ever, expression of the wild-type IGF-IR accelerated tumor
growth and tumors were larger at sacrifice. The kinase de-
fective IGF-IR, on the other hand, delayed the appearance
of tumors and smaller tumors were found at sacrifice.
The tumors were imbedded in paraffin and sections were
stained with hematoxylin and eosin (Figure 2, left pan-
els). The sections were also stained for the presence of ap-
optosis using the TUNEL method. Apoptotic cells image
as fluorescent green (Figure 2, right panels). The typical
histology of CHO tumors is shown in panel A. Cells trans-
fected with the wild-type IGF-IR have a more streaming
morphology characteristic of human ovarian tumors
(Panel B). Cells transfected with the kinase-defective IGF-
IR showed a more benign morphology with no invasion
of the capsule (Panel C and data not shown). Very few ap-
optotic cells are seen in the CHO parental and CHO-WT
cells, whereas apoptotic cells are seen throughout the tu-
mor from the kinase-defective CHO-MK cells. These re-
sults confirm that the kinase defective IGF-IR is able to
inhibit tumor growth in a model system.
An inhibitory antibody to the IGF-IR inhibits growth of U87 
tumors
Adenoviral expression of wild-type PTEN can inhibit U87
tumor growth indicating that elevated PI-3Kinase signal-
ing is responsible for the increased proliferation and sur-
vival of these cells [47,54]. Our subsequent studies were
designed to test whether interruption of an upstream
growth factor signal would have the same growth inhibi-
tory effect as reintroduction of PTEN. To test initially
whether the PTEN-deficient U87 glioma cells might be
susceptible to inhibition of the IGF-IR, we measured col-
ony formation and tumor growth in the presence of an in-
hibitory antibody to the human IGF-IR (α IR3). This
antibody prevents binding of IGF-I or IGF-II to the extra-
cellular domain of the IGF-IR, and has been shown to pre-
Figure 2
Staining of CHO cell tumors. Left panels: hematoxylin-eosin
staining of sections of CHO (panel A), CHO-WT (panel B),
and CHO-MK (panel C) tumors. Right panels: TUNEL stain-
ing for apoptotic cells. Apoptotic cells were detected with a
fluorescein labeled secondary antibody and show green fluo-
rescence.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/15
Page 6 of 9
(page number not for citation purposes)
vent the formation of MDA231 tumors in nude mice [55].
U87 cells were plated in soft agar in the presence of α IR3
or a control antibody. Cells were cultured for 14 days and
the number of colonies counted. The presence of the in-
hibitory antibody reduced the number of colonies grow-
ing in soft agar but the control antibody had no effect
(Table 1). U87 cells were then injected into nude mice as
before. Mice received biweekly intraperitoneal injections
of 100 µg of α IR3 or control antibody starting 3 days after
injection of the cells. The α IR3 injections reduced the
number of tumors by >60% (Table 1). The tumors were
excised, fixed and stained for apoptosis. Tumors from
mice treated with the α IR3 antibody showed extensive ap-
optosis unlike control tumors (Figure 3). These results
confirm that inhibition of IGF-I signaling by an inhibitory
antibody can suppress growth of a PTEN-deficient glioma
cell line.
Retroviral expression of the kinase inactive IGF-I Receptor 
inhibits growth of U87 glioblastoma cells in-vivo
To make expression of kinase defective IGF-I receptors in
different cell lines more tractable, we generated pseudo-
typed retroviruses expressing either the kinase-defective
(MK) or wild-type (WT) IGF-I receptors. We also obtained
a virus expressing the beta-galactosidase (LacZ) protein to
measure infection efficiency and serve as a virus control.
U87 cells were infected with the MK, WT or LacZ viruses
and selected with G418. Pools of cells containing stably
integrated retroviruses were then used in transformation
and tumor growth experiments. Binding studies showed
that the U87-LacZ cells express 105 endogenous IGF-IRs
per cell, while the U87-WT and U87-MK cells express 3 ×
106 and 2 ×  106 receptors per cells respectively. Thus, the
retrovirus allows 20 to 30-fold overexpression of the
transfected receptor.
To test the function of the virally encoded receptors, we
measured IGF-I stimulated autophosphorylation of the
IGF-IR and phosphorylation of IRS-1. Phosphorylation
IRS-1 was evident in the LacZ infected cells but little IGF-
IR phosphorylation was seen as the cells express few re-
ceptors (Figure 4). Infection with the WT virus leads to a
large increase in IGF-IR and IRS-1 tyrosine phosphoryla-
tion. Infection with the MK virus eliminated the IGF-I
stimulated phosphorylation of IRS-1 confirming that the
expressed receptor was acting as a dominant negative to
inhibit the endogenous receptors. The dominant negative
effect is much greater in these cells than the CHO cells
(Figure 1) as the virus expresses the transfected receptors
at a much higher level.
The three infected U87 glioma cells were then injected
into nude mice. Eight to twelve mice were studied for each
cell line and each mouse received two injections. In two
different experiments, mice were inoculated with 106 or 5
×  105 cells. Tumors were excised after 6 or 10 weeks and
weighed (Table 2). The WT-infected cells had the highest
frequency of tumor formation and the MK-infected cells
the lowest in both cases. WT-infected cells gave the largest
tumors in both experiments demonstrating that overex-
pression of the IGF-IR in a malignant cell can enhance tu-
mor formation as we observed for the CHO cells. The MK-
infected cells gave fewer tumors in both experiments, but
more importantly, those tumors that did form were much
smaller. The results obtained with the dominant negative
IGF-IR are identical to published results reintroducing
PTEN, hence, inhibition of upstream PI-3Kinase signaling
might be a useful approach for PTEN-deficient tumors.
The tumors were imbedded in paraffin and sections were
stained with hematoxylin and eosin (Figure 5). The U87-
Table 1: Effect of antibody α IR3 on transformation and tumor 
growth.
Untreated α IR3 Mouse IgG
Colonies in soft agar 28 ± 3 11 ± 2 27 ± 2
Tumors in nude mice - 4/16 (25%) 11/16 (69%)
Figure 3
Treatment with an inhibitory antibody against the IGF-IR.
One million U87 cells were injected subcutaneously into the
rear flanks of athymic nude mice. Mice received intraperito-
neal injections of 100 µg of α IR3 or control IgG every two
days starting on the third day after inoculation with cells.
Each group consisted of eight mice that each received two
injections of cells. Tumors were excised, fixed, sectioned and
stained for apoptosis using the TUNEL assay. Left panel
shows tumor from mice treated with control IgG; right panel
shows tumor from mice treated with α IR3. TUNEL positive
cells show green fluorescence.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/15
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LacZ tumors are very cellular with small regular nuclei
(left panel) and show some invasion of the capsule by tu-
mor cells (right panel). The tumors from U87 cells infect-
ed with the IGF-IR virus are also very cellular, but the cells
have larger nuclei (left panel) and have completely invad-
ed the capsule (right panel). The tumors from U87 cells
infected with the kinase inactive IGF-IR are less cellular
with larger areas of stroma (left panel). Numerous irregu-
lar nuclei are apparent. There is no invasion of the capsule
by tumor cells (right panel). The irregular nuclei and in-
tact capsule are consistent with data from other cells
showing that inhibition of IGF-IR expression causes apop-
tosis and prevents metastasis.
The idea that the IGF-IR might be a valuable target for the
treatment of brain tumors is supported by a recent pilot
study in twelve patients with malignant astrocytomas
[56]. All patients had grade 3 or 4 astrocytomas and had
failed on standard therapy. The PTEN status of their pri-
mary tumors was not known. After surgery, autologous
glioma cells were collected and treated ex-vivo with IGF-
IR antisense oligos and re-implanted in diffusion cham-
Table 2: Growth of infected U87 cells in nude mice.
U87 U87-WT U87-MK
# cellsa #tumors (%) Weight (g) #tumors (%) Weight (g) #tumors (%) Weight (g)
5 ×  105 4/14 (29%) 0.48 ± 0.11 11/16 (69%) 0.67 ± 0.15 2/14 (14%) 0.13* ± 0.02
106 16/24 (67%) 0.43 ± 0.13 16/18 (89%) 0.57 ± 0.1 11/24 (46%) 0.12* ± 0.02
Weight is given as mean ± SEM. (a) mice with 5 ×  105 cells sacrificed after 10 weeks, mice with 106 cells sacrificed after 6 weeks. Asterisks denote 
statistical significance (P < 0.05) versus parental cells
Figure 4
Retroviral expression of wild-type and mutant IGF-IRs in
U87 glioma cells. U87 cells stably infected with pseudotyped
retroviruses expressing β -galactosidase (LacZ), wild-type
IGF-IR (WT) or kinase defective IGF-IR (MK) were rendered
quiescent by serum-starvation then stimulated with IGF-I (10
or 100 ng/ml) for 5 min. Whole cell extracts were immunob-
lotted for phosphotyrosine. The positions of the β -subunit of
the IGF-IR and the IRS proteins are indicated.
IGF-I:     0     10   100    0     10   100   0      10   100   ng/ml
IGF-IR
IRS
Virus:           LacZ                WT                 MK
Figure 5
Staining of U87 tumors. Tumors were fixed, sectioned and
stained with hematoxylin-eosin. Left panels: staining of cen-
tral tumor section. Right panels: staining of tumor capsule.
White arrows indicate infiltration of tumor cells into the cap-
sule. Tumors from U87-LacZ cells are shown in the top pan-
els, tumors from U87-WT cells (wild-type IGF-IR) in the
middle panels, and tumors from U87-MK cells (kinase defec-
tive IGF-IR) in the bottom panels.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/15
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bers for 24 h. Clinical and radiological improvements
were seen in eight of the twelve patients. Five patients
showed a lymphocytic infiltration after antisense treat-
ment indicating that knocking out the IGF-IR induced an
immune response. It would be interesting to determine
whether response to this treatment correlated with loss of
PTEN in the primary tumors.
Conclusions
Loss of PTEN is a very common occurrence in human tu-
mors. Restoring PTEN protein or function to reduce PI-
3Kinase signaling prevents tumor growth in animal mod-
els. However, it may not be possible to restore PTEN in
human tumors. Direct inhibition of PI-3Kinase activity
may not be feasible either as it is likely to have severe side
effects. Our results suggest that a therapeutic strategy to in-
hibit the upstream stimulus for PI-3Kinase through block-
ade of growth factor receptors may provide a workable
alternative.
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